Literature DB >> 22155504

Important drug interactions in hematopoietic stem cell transplantation: what every physician should know.

Brett Glotzbecker1, Christine Duncan, Edwin Alyea, Bonnie Campbell, Robert Soiffer.   

Abstract

Morbidity is increased in patients undergoing hematopoietic stem cell transplantation when drug-drug interactions lead to unexpected outcomes. These interactions occur as a result of exposure to complicated medical regimens with drugs with narrow therapeutic windows and high toxicity profiles. In this report, we review the available evidence and possible mechanisms of the most clinically relevant drug interactions, including those involving inhibitors and inducers of the P450 isoenzyme system. We identify key interactions that should be familiar to any physician caring for patients after hematopoietic stem cell transplantation. We discuss drug metabolism in children and in the elderly and examine how age-related differences in metabolism make complicate drug regimens in these populations. A better understanding of these interactions and the responsible mechanisms will promote efficient delivery of the safest medical regimens to patients undergoing hematopoietic stem cell transplantation.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155504     DOI: 10.1016/j.bbmt.2011.11.029

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  20 in total

1.  Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation.

Authors:  Mitsutaka Nishimoto; Hideo Koh; Atsushi Tokuwame; Yosuke Makuuchi; Masatomo Kuno; Teruhito Takakuwa; Hiroshi Okamura; Shiro Koh; Takuro Yoshimura; Satoru Nanno; Mika Nakamae; Asao Hirose; Yasuhiro Nakashima; Takahiko Nakane; Masayuki Hino; Hirohisa Nakamae
Journal:  Br J Clin Pharmacol       Date:  2017-05-24       Impact factor: 4.335

2.  Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.

Authors:  Alex Ganetsky; Todd A Miano; Mitchell E Hughes; Robert H Vonderheide; David L Porter; Ran Reshef
Journal:  J Antimicrob Chemother       Date:  2015-04-16       Impact factor: 5.790

3.  Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond.

Authors:  Marcelo C Pasquini; Alok Srivastava; Syed Osman Ahmed; Mahmoud Aljurf; Yoshiko Atsuta; Carol Doleysh; Sebastian Galeano; Eliane Gluckman; Hildegard Greinix; Gregory Hale; Parameswaran Hari; Shahrukh K Hashmi; Naynesh Kamani; Mary J Laughlin; Dietger Niederwieser; Adriana Seber; Jeffrey Szer; John A Snowden; Koen Van Biesen; Paula Watry; Daniel J Weisdorf; Jane Apperley
Journal:  Hematol Oncol Stem Cell Ther       Date:  2019-08-20

4.  Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.

Authors:  Su-Peng Yeh; Woei-Chung Lo; Ching-Yun Hsieh; Li-Yuan Bai; Ching-Chan Lin; Po-Han Lin; Chen-Yuan Lin; Yu-Min Liao; Chang-Fang Chiu
Journal:  Support Care Cancer       Date:  2013-12-07       Impact factor: 3.603

Review 5.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

6.  Disseminated Bacillus Calmette-Guérin (BCG) infection following allogeneic hematopoietic stem cell transplant in a patient with Bare Lymphocyte Syndrome type II.

Authors:  R F Abu-Arja; B E Gonzalez; M R Jacobs; L Cabral; R Egler; J Auletta; J Arnold; K R Cooke
Journal:  Transpl Infect Dis       Date:  2014-07-04       Impact factor: 2.228

7.  Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.

Authors:  Kimitaka Suetsugu; Hiroaki Ikesue; Toshihiro Miyamoto; Motoaki Shiratsuchi; Nanae Yamamoto-Taguchi; Yuichi Tsuchiya; Kumi Matsukawa; Mayako Uchida; Hiroyuki Watanabe; Koichi Akashi; Satohiro Masuda
Journal:  Int J Hematol       Date:  2016-11-07       Impact factor: 2.490

Review 8.  Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Daping Zhang; Diana S-L Chow
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

9.  Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.

Authors:  Rakesh K Goyal; Kelong Han; Donna A Wall; Michael A Pulsipher; Nancy Bunin; Stephan A Grupp; Sripal R Mada; Raman Venkataramanan
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-21       Impact factor: 5.742

Review 10.  Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Authors:  Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-08-17       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.